Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment

被引：50
作者：
Anderson, Timothy S. [1 ]
Ayanian, John Z. [2 ]
Souza, Jeffrey [3 ]
Landon, Bruce E. [3 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Div Gen Med, 1309 Beacon St, Boston, MA 02246 USA
[2] Univ Michigan, Inst Hlthcare Policy & Innovat, Ann Arbor, MI USA
[3] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2021年 / 326卷 / 16期
关键词：
D O I：
10.1001/jama.2021.15286
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1627 / 1629
页数：3
相关论文
共 4 条
[1]   Evaluation of Aducanumab for Alzheimer Disease Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility [J].
Alexander, G. Caleb ;
Emerson, Scott ;
Kesselheim, Aaron S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (17) :1717-1718
[2]  
Center for Medicare & Medicaid Services, CHRONIC CONDITIONS D
[3]   Evaluation of Medicare Claims Data as a Tool to Identify Dementia [J].
Lee, Eunjung ;
Gatz, Margaret ;
Tseng, Chiuchen ;
Schneider, Lon S. ;
Pawluczyk, Sonia ;
Wu, Anna H. ;
Deapen, Dennis .
JOURNAL OF ALZHEIMERS DISEASE, 2019, 67 (02) :769-778
[4]  
US Food & Drug Administration, ADUCANUMAB MARKETED
1